Sideris Spyridon, Aoun Fouad, Zanaty Marc, Martinez Nieves Chanza, Latifyan Sofia, Awada Ahmad, Gil Thierry
Medical Oncology Clinic, Jules Bordet Institute, 1000 Brussels, Belgium.
Department of Urology, Jules Bordet Institute, 1000 Brussels, Belgium.
Mol Clin Oncol. 2016 Jun;4(6):1063-1067. doi: 10.3892/mco.2016.821. Epub 2016 Mar 17.
The aim of the present study was to investigate the efficacy of paclitaxel following a first-line cisplatin regimen in patients with metastatic bladder cancer. The present study retrospectively evaluated the clinical effects and toxicities of second-line paclitaxel regimens following first-line cisplatin treatment in metastatic bladder cancer. A total of 42 patients with progressing metastatic urothelial bladder cancer following cisplatin-based chemotherapy were enrolled. The patients received weekly treatment with paclitaxel (80 mg/m) with a median duration of 3 months. The overall response rate, disease control rate and median progression free survival were 9.5, 45.2 and 6.4 months, respectively. Weekly paclitaxel was well-tolerated with rare grade III or IV toxicities. Second-line weekly paclitaxel treatment following first-line cisplatin-based chemotherapy is an effective and well-tolerated regimen in urothelial metastatic bladder cancer.
本研究的目的是调查紫杉醇在转移性膀胱癌患者一线顺铂治疗方案后的疗效。本研究回顾性评估了转移性膀胱癌患者一线顺铂治疗后二线紫杉醇方案的临床疗效和毒性。共有42例接受以顺铂为基础化疗后病情进展的转移性尿路上皮膀胱癌患者入组。患者接受每周一次的紫杉醇治疗（80mg/m），中位疗程为3个月。总缓解率、疾病控制率和中位无进展生存期分别为9.5%、45.2%和6.4个月。每周一次的紫杉醇耐受性良好，罕见III级或IV级毒性。一线顺铂为基础的化疗后二线每周一次的紫杉醇治疗是尿路上皮转移性膀胱癌的一种有效且耐受性良好的方案。
